Gout and Hyperuricemia Management in Developing Countries

Gout and hyperuricemia, characterized by elevated levels of uric acid in the bloodstream, have emerged as significant health concerns in developing countries. The prevalence of gout and hyperuricemia has been steadily rising in developing countries, driven by shifting lifestyles, dietary patterns, and an aging population. Despite their perception as conditions primarily affecting affluent societies, gout and hyperuricemia have become increasingly prevalent in resource-constrained settings, posing unique challenges. The morbidity associated with gout and hyperuricemia is profound, with recurrent painful attacks affecting joints, tissues, and organs. Furthermore, these conditions are linked to an increased risk of comorbidities such as cardiovascular disease and kidney dysfunction. In developing countries, where healthcare resources may be limited, addressing the clinical presentation and diagnosis of these conditions is particularly crucial. Risk factors, including genetics, diet, alcohol consumption, and comorbidities, play a significant role in gout and hyperuricemia. Developing countries often face a higher burden of these risk factors, compounding the challenges of managing these conditions. Complications of gout, such as tophi formation and joint destruction, can result in severe disability and reduced quality of life. The economic and humanistic burden of gout and hyperuricemia in developing countries underscores the need for effective interventions. This chapter emphasizes recommendations to enhance gout and hyperuricemia management in developing countries, including healthcare infrastructure development, patient education, and leveraging online resources. By addressing the unique challenges faced by these regions, it is possible to improve the care and outcomes of individuals affected by gout and hyperuricemia, reducing their burden on healthcare systems and society as a whole.